Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Operating Leases (2019 - 2024)

Arcadia Biosciences (RKDA) has disclosed Operating Leases for 6 consecutive years, with $11000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Operating Leases fell 97.93% year-over-year to $11000.0, compared with a TTM value of $11000.0 through Jun 2024, down 97.93%, and an annual FY2023 reading of $155000.0, down 84.61% over the prior year.
  • Operating Leases was $11000.0 for Q2 2024 at Arcadia Biosciences, down from $21000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $5.7 million in Q2 2021 and bottomed at $11000.0 in Q2 2024.
  • Average Operating Leases over 5 years is $2.5 million, with a median of $1.6 million recorded in 2022.
  • The sharpest move saw Operating Leases surged 284.41% in 2020, then tumbled 97.93% in 2024.
  • Year by year, Operating Leases stood at $5.4 million in 2020, then crashed by 58.8% to $2.2 million in 2021, then crashed by 54.64% to $1.0 million in 2022, then tumbled by 84.61% to $155000.0 in 2023, then plummeted by 92.9% to $11000.0 in 2024.
  • Business Quant data shows Operating Leases for RKDA at $11000.0 in Q2 2024, $21000.0 in Q1 2024, and $155000.0 in Q4 2023.